Search Result

Results for "

L-2-Aminopropionic acid-<sup>15</sup>N,d<sub>4</sub>

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Endogenous Metabolite (8) GCGR (3) GLP Receptor (2) Isotope-Labeled Compounds (4) Vasopressin Receptor (1)
By Research Areas:	Cardiovascular Disease (1) Metabolic Disease (12) Neurological Disease (7)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: Amino acid Transporter Amino Acid Derivatives Amino Acid Decarboxylase Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter P-glycoprotein G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0229S9

L-Alanine-13C2 L-2-Aminopropionic acid-<sup>13sup>C<sub>2sub>	Endogenous Metabolite	Neurological Disease Metabolic Disease
L-Alanine- ¹³C₂ is the ¹³C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S15

L-Alanine-13C2,15N L-2-Aminopropionic acid-<sup>13sup>C<sub>2sub>,<sup>15sup>N	Endogenous Metabolite	Metabolic Disease
L-Alanine- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S10

L-Alanine-13C3,15N L-2-Aminopropionic acid-<sup>13sup>C<sub>3sub>,<sup>15sup>N	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
L-Alanine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S4

L-Alanine-13C,d1 L-2-Aminopropionic acid-<sup>13sup>C,d<sub>1sub>	Endogenous Metabolite	Neurological Disease Metabolic Disease
L-Alanine- ¹³C,d is the ¹³C- and deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S8

L-Alanine-13C3 L-2-Aminopropionic acid-<sup>13sup>C<sub>3sub>	Endogenous Metabolite	Neurological Disease Metabolic Disease
L-Alanine- ¹³C₃ is the ¹³C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N2362S9

DL-Alanine-13C2,15N DL-2-Aminopropionic acid-<sup>13sup>C<sub>2sub>,<sup>15sup>N<sub>2sub>	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
DL-Alanine- ¹³C₂, ¹⁵N (DL-2-Aminopropionic acid- ¹³C₂, ¹⁵N) is ¹³C and ¹⁵N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .

HY-N0229S14

L-Alanine-15N,d4 L-2-Aminopropionic acid-<sup>15sup>N,d<sub>4sub>	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
L-Alanine- ¹⁵N,d₄ is the deuterium and ¹⁵N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S5

L-Alanine-13C3,15N,d4 L-2-Aminopropionic acid-<sup>13sup>C<sub>3sub>,<sup>15sup>N,d<sub>4sub>	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Metabolic Disease
L-Alanine- ¹³C₃, ¹⁵N,d₄ is the deuterium, ¹³C-, and 15-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

Cat. No.	Product Name	Target	Research Area

HY-P4146

Survodutide BI 456906	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P4146A

Survodutide TFA BI 456906 TFA	GLP Receptor GCGR	Metabolic Disease
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .

HY-P10876

mcK6A1	Amyloid-β	Neurological Disease
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .

HY-P2595

SKF 103784	Peptides	Cardiovascular Disease
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .

HY-P10341

ZP3022	GCGR	Metabolic Disease
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .

HY-P1162

(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin SKF 100273	Vasopressin Receptor	Metabolic Disease
(d(CH2)51,Tyr(Me)2,Arg8)-Vasopressin (SKF 100273) is a vasopressin V1 receptor selective antagonist .

Cat. No.	Product Name	Chemical Structure

HY-N0229S9

L-Alanine-13C2
L-Alanine- ¹³C₂ is the ¹³C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S15

L-Alanine-13C2,15N
L-Alanine- ¹³C₂, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S10

L-Alanine-13C3,15N
L-Alanine- ¹³C₃, ¹⁵N is the ¹³C- and ¹⁵N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S4

L-Alanine-13C,d1
L-Alanine- ¹³C,d is the ¹³C- and deuterium labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S8

L-Alanine-13C3
L-Alanine- ¹³C₃ is the ¹³C-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N2362S9

DL-Alanine-13C2,15N
DL-Alanine- ¹³C₂, ¹⁵N (DL-2-Aminopropionic acid- ¹³C₂, ¹⁵N) is ¹³C and ¹⁵N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .

DL-Alanine-13C2,15N

DL-Alanine- ¹³C₂, ¹⁵N (DL-2-Aminopropionic acid- ¹³C₂, ¹⁵N) is ¹³C and ¹⁵N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .

HY-N0229S14

L-Alanine-15N,d4
L-Alanine- ¹⁵N,d₄ is the deuterium and ¹⁵N-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

HY-N0229S5

L-Alanine-13C3,15N,d4
L-Alanine- ¹³C₃, ¹⁵N,d₄ is the deuterium, ¹³C-, and 15-labeled L-Alanine. L-Alanine is a non-essential amino acid, involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and central nervous system.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.